Arrowstreet Capital
SYRE icon

Arrowstreet Capital’s Spyre Therapeutics SYRE Stock Holding History

Arrowstreet Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-504
Closed -$89K – 2531
2020
Q3 		$89K Buy
+504
New +$93.2K ﹤0.01% 2261

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Arrowstreet Capital's SYRE Position: Q4 2020 in Review

Arrowstreet Capital sold out of Spyre Therapeutics (SYRE) in Q4 2020, closing a stake of 504 shares — an estimated $89K sold.

Arrowstreet Capital first reported a position in SYRE in Q3 2020 and held it in 1 quarter. The position peaked at $89K in Q3 2020. 92 funds tracked by Wall St. Rank hold SYRE as of Q4 2020.

  • Arrowstreet Capital reported no remaining Spyre Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 504 Spyre Therapeutics shares in Q4 2020, an estimated $89K.
  • Arrowstreet Capital first reported a position in Spyre Therapeutics in Q3 2020 and held it in 1 quarter.
  • Arrowstreet Capital's Spyre Therapeutics position peaked at $89K in Q3 2020.
  • 92 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2020.

Based on Arrowstreet Capital's 13F filing for Q4 2020, filed 12 Feb 2021.